Project Grant R01AI201177
Award Date 9/3/26
Completion Date 8/31/31
Dollars Obligated $534K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Durham, NC 27710, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases awarded Duke University $444,125 on April 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to accelerate T cell immune reconstitution following cultured thymus tissue implantation (CTTI). The research addresses the urgent clinical need to speed immune recovery after thymus transplantation, which currently risks early post-transplant deaths from infection before immune reconstitution occurs. Duke's prior...
- The National Institute of Allergy and Infectious Diseases awarded Duke University $783,701 on May 22, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate the development and contribution of individual plasma B cells to broad HIV serum neutralization. Duke will conduct high-throughput antibody sequencing to recover antibody sequences from plasma cells in mice immunized with a novel regimen, produce selected antibodies from those sequences, and...
- The National Institute of Allergy and Infectious Diseases awarded The Trustees of Columbia University in the City of New York $622,850 on September 2, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate the heterogeneous functions, antigen specificities, and lipid antigen restrictions of human CD4-/CD8- double-negative T cells (DN T cells). The research examines how CD1-restricted DN T cell populations respond to CD1-presented self-lipid antigens and...
- The National Institute of Allergy and Infectious Diseases awarded Duke University $242,250 on June 22, 2026, to investigate how regulatory T cells suppress anti-breast cancer immunity and to identify molecular targets for therapeutic intervention under the Allergy and Infectious Diseases Research program (CFDA 93.855). The research focuses on strawberry notch homologs and their role in regulatory T cell-mediated suppression of anti-tumor immune responses. The project team identified a previously...
- The National Institute of Allergy and Infectious Diseases awarded Duke University $684,405 on July 22, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop mucosal immunotherapies targeting recurrent urinary tract infections and inflammatory bowel disease. The funded research advances immunomodulation via self-assembled peptides (ISAP), a platform using modular supramolecular polypeptide nanomaterials designed to elicit neutralizing antibody responses against...
- The National Institute of Allergy and Infectious Diseases awarded the University of North Carolina at Chapel Hill $427,625 on April 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The recipient will evaluate the efficacy of coreceptor therapy using low-dose nondepleting anti-CD4 antibodies to induce de-differentiation of autoreactive T follicular helper cells (TFH) and promote their conversion into functional regulatory T cells (TREG) in the context of type 1...
- The National Institute of Allergy and Infectious Diseases awarded Duke University $806,623 on May 29, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855, Project Grant R56AI194947) to elucidate the structural and kinetic basis of HIV-1 broadly neutralizing antibody responses, focusing on transient states and intermediates in antibody-antigen interactions that govern affinity maturation and neutralization breadth. The funded research will employ structural and kinetic...
- The National Institute of Allergy and Infectious Diseases awarded New York University $755,801 on February 3, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct research on the regulation of CD4+ and CD8+ T cell function by CLNS1A. The research examines the mechanisms controlling T lymphocyte function in immunity to infection and cancer, as well as in autoimmune and allergic diseases. The project uses forward genetics screens in animal models of brain and...
- The National Institute of Allergy and Infectious Diseases awarded Duke University $866,664 on August 3, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct research on antigen-specific MHC-E-mediated NK-cell targeting of the HIV/SIV reservoir. The award funds research developing and testing approaches to harness adaptive NK cells to suppress and eliminate HIV and SIV reservoirs. The work comprises three primary aims: developing single chain MHC-E-based...
- The National Institute of Allergy and Infectious Diseases awarded Duke University $2,342,550 on May 8, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop a combined T cell and B cell therapeutic countermeasure to achieve functional cure of HIV-1 infection. The research combines two immunological approaches: a CD8 T cell countermeasure using an integrase-deficient lentiviral vector delivering the viral GAG gene to control viremia, and a B cell countermeasure...